literature

HIV mutation literature information.

Outcome of patients on second line antiretroviral therapy under programmatic condition in India.

PMID: 26572102 2015 BMC infectious diseases

Result: 81.25 % (n = 13) had more than 1 NNRTI mutation.Y181C and G190A was the most common NNRTI mutation present in 37.5 % (n = 6) patient each.

Table: G190A

Lack of integrase inhibitors associated resistance mutations among HIV-1C isolates.

PMID: 26626277 2015 Journal of translational medicine

Result: As previously reported in this group of well characterized patients, two patients had NNRTI associated mutations (G190A and E138G) and one patient had a NRTI resistance-associated mutation (L210 W).

Table: G190A

HIV-1 subtype characteristics of infected persons living in southwestern Greece.

PMID: 26715861 2015 HIV/AIDS (Auckland, N.Z.)

Result: The 22 cases experiencing virologic failure presented with the following DRMs: M46I, F53LY, I54LTV, G73ST, L76V, V82AT, I84V, I185V, N88D, and L90M for PIs; L100I, K103NS, V179F Y181C, G190AS, V106A, K103N, and P225H for NNRTIs; and

HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.

PMID: 26717411 2015 PloS one

Result: K103N, Y181C and G190A were the three most common NNRTI DRMs in all regions and subtypes, occurring in more than 60% of viruses with intermediate or high-level

Result: Fig 2 shows that the most common NNRTI DRMs in viruses from individuals in LMICs with intermediate or high-level resistance on a first-line NRTI/NNRTI-containing regimen were K103N (45.5%), Y181C (27.0%), G190A (21.0%), and V106M (18.7%).

Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.

PMID: 23934770 2014 The Journal of antimicrobial chemotherapy

Abstract: RESULTS: Sixteen mutations at 10 positions were significantly associated with the greatest contribution to reduced phenotypic susceptibility (>=10-fold) to one or more NNRTIs, including: 14 mutations at six positions for nevirapine (K101P, K103N/S, V106A/M, Y181C/I/V, Y188C/L and G190A/E/Q/S); 10 mutations at six positions for efavirenz (L100I, K101P, K103N, V106M, Y188C/L and G190A/E/Q/S); 5 mutations at four positions for etravirine (

PMID: 24164431 2014 AIDS research and human retroviruses

Abstract: The specific SDRMs detected were M41L for nucleoside reverse transcriptase inhibitors (NRTIs) and G190A for nonnucleoside reverse transcriptase inhibitors (NNRTIs).

HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study.

PMID: 24456757 2014 AIDS research and therapy

Table: G190A

Characteristics of HIV-1 natural drug resistance-associated mutations in former paid blood donors in Henan Province, China.

PMID: 24586665 2014 PloS one

Result: K101E and G190A caused high resistance to NVP, intermediate resistance to EFV, and low resistance to ETR and RPV.

Result: G190A accounted for 1.9%, and caused high level resistance to NVP and intermediate resistance to EFV.

Result: HNHIV46, HNHIV74, HNHIV77, and HNHIV137 were clustered together, with HNHIV46 and HNHIV137 having A71V, D67N, K101E, and G190A mutations, HNHIV74 having A71T mutation, and HNHIV77 having A71V and K103N mutations.

Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.

PMID: 24633208 2014 The Journal of antimicrobial chemotherapy

Result: Individual mutations observed were G190AS (n = 8; 47%), Y181CV (n = 6; 35%), K101I (n = 3; 18%), A98G (n = 2; 12%), K103N (n = 2; 12%) and V108I (n = 1; 6%).

Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia.

PMID: 24708645 2014 BMC infectious diseases

Discussion: In a study conducted in Gondar, only two mutations (V75I and G190A) were detected among 92 ART-naive patients in 2003, before ART roll out.

Browser Board

Co-occurred Entities

Filtrator